Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded to enhance late-stage drug development, 9vc specializes in creating and investing in companies that focus on drug reincarnation for patients. The organization employs a proprietary search engine to identify and build tech-bio partnerships, facilitating innovative solutions in the biotech sector.
Currently, 9vc operates with a focus on late-stage investments, particularly in Series C and growth equity rounds. The firm has a notable portfolio company, Leona Bio (NASDAQ: LONA), which is advancing a phase 2 ready pipeline in drug development. 9vc's approach combines technology and expertise to reduce risk and accelerate value realization, making it a key player in the biotech investment landscape.
9vc invests primarily in late-stage clinical development companies, particularly those involved in drug development within the biotech and healthcare sectors. The organization emphasizes asset arbitrage, aiming to capture value in opportunities that may be overlooked by others. Their investment strategy combines technology and expertise to mitigate risks and expedite the realization of value.
Investment checks typically align with Series C and growth equity stages, allowing 9vc to support companies that are nearing significant milestones in their drug development processes. The firm actively seeks partnerships that enhance the potential for successful outcomes in the biotech field.
9vc's portfolio includes:
Anat Naschitz: Investor, Company and Fund Creator with a focus on biotech investments.
Jan Schultink: Tech Entrepreneur and Builder with experience in scaling biotech companies.
Jeremy Levin: Advisory Board Chairman and CEO of OvidRx, bringing extensive leadership experience in the biotech sector.
Paul Sekhri: Advisory Board CEO of vTv, with a strong background in healthcare management.
Danny Bar-Zohar: Advisory Board CEO of Merck KGaA Healthcare, contributing deep industry insights.
Johan Luthman: Advisory Board R&D Leader with expertise in drug development.
Aaron Gershenberg: Advisory Board CEO of Blue Chip Funds of Funds, with a focus on investment strategies.
Paul Biondi: Advisory Board General Partner and President of Flagship Pioneering Medicines, known for his leadership in biotech innovation.
To pitch to 9vc, founders should visit 9vc.co and submit their proposals through the provided channels. It is recommended to include comprehensive details about the startup's drug development initiatives and expected outcomes.
As of October 2023, 9vc continues to focus on late-stage drug development investments, particularly in the biotech sector. Their portfolio company, Leona Bio, is advancing its phase 2 ready pipeline, which includes treatments for ESR1-mutant metastatic breast cancer and neurodegenerative diseases.
9vc's emphasis on asset arbitrage and technology-driven partnerships positions them as a significant player in the biotech investment landscape, attracting attention from startups seeking growth equity.
What are 9vc's investment criteria?
9vc focuses on late-stage clinical development companies, particularly in the biotech and healthcare sectors. They emphasize asset arbitrage and seek to invest in opportunities that may be overlooked by others.
How can I pitch to 9vc?
Founders can submit their pitches through the official website at 9vc.co. It is advisable to include detailed information about the company's drug development programs and potential market impact.
What makes 9vc different from other investors?
9vc combines technology and expertise to reduce risk and accelerate value realization in drug development, focusing on late-stage investments that leverage asset arbitrage.
What is the geographic scope of 9vc's investments?
While specific geographic preferences are not detailed, 9vc primarily invests in companies within the biotech and healthcare sectors, which may include a global focus.
What is the typical check size for investments?
9vc typically invests in Series C and growth equity rounds, which suggests check sizes are aligned with late-stage funding requirements, although specific amounts are not disclosed.
What kind of post-investment involvement does 9vc have?
9vc's team includes experienced professionals from the biotech sector, which suggests they may provide operational support and strategic guidance to portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.